Citadel Advisors’s Cardiol Therapeutics CRDL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$807K Sell
486,246
-310,283
-39% -$494K ﹤0.01% 9033
2026
Q2
$844K Sell
796,529
-23,375
-3% -$29.6K ﹤0.01% 8633
2026
Q1
$1.11M Buy
+819,904
New +$841K ﹤0.01% 7440
2025
Q4
– Sell
-463,462
Closed -$485K – 12828
2025
Q3
$496K Buy
+463,462
New +$562K ﹤0.01% 9162
2025
Q1
– Sell
-38,110
Closed -$46.8K – 14617
2024
Q4
$48.8K Buy
38,110
+31,889
+513% +$53.8K ﹤0.01% 12417
2024
Q3
$12.3K Sell
6,221
-19,966
-76% -$41.4K ﹤0.01% 13112
2024
Q2
$52.9K Sell
26,187
-34,211
-57% -$72.6K ﹤0.01% 11692
2024
Q1
$109K Buy
+60,398
New +$81.4K ﹤0.01% 11228
2023
Q3
– Sell
-17,743
Closed -$15.8K – 14385
2023
Q2
$15.8K Sell
17,743
-973
-5% -$642 ﹤0.01% 12924
2023
Q1
$9.12K Buy
+18,716
New +$11.1K ﹤0.01% 13606
2022
Q4
– Sell
-46,204
Closed -$28.2K – 14927
2022
Q3
$48K Buy
46,204
+22,313
+93% +$27.2K ﹤0.01% 11660
2022
Q2
$32K Sell
23,891
-4,561
-16% -$6.49K ﹤0.01% 12181
2022
Q1
$44K Sell
28,452
-148,617
-84% -$245K ﹤0.01% 12878
2021
Q4
$328K Buy
+177,069
New +$489K ﹤0.01% 10727

Other funds holding CRDL

Citadel Advisors's CRDL Position: Q3 2026 in Review

Citadel Advisors reduced its Cardiol Therapeutics (CRDL) stake by 39% in Q3 2026, selling an estimated $494K and leaving 486,246 shares worth $807K. The position accounts for ﹤0.01% of the portfolio, ranked #9033.

Citadel Advisors first reported a position in CRDL in Q4 2021 and has held it in 14 quarters since. The position peaked at $1.11M in Q1 2026. 59 funds tracked by Wall St. Rank hold CRDL as of Q3 2026.

  • Citadel Advisors held 486,246 shares of Cardiol Therapeutics worth $807K as of Q3 2026.
  • Citadel Advisors sold 310,283 Cardiol Therapeutics shares in Q3 2026, an estimated $494K.
  • Cardiol Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q3 2026, its #9033 holding.
  • Citadel Advisors first reported a position in Cardiol Therapeutics in Q4 2021 and has held it in 14 quarters since.
  • Citadel Advisors's Cardiol Therapeutics position peaked at $1.11M in Q1 2026.
  • 59 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q3 2026.

Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.